ReviewFrontiers in pharmacology2026
Targeting ferroptosis in osteoporosis: mechanisms and natural products therapies.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis (OP) persists as the principal contributor to the global disease burden. OP is defined by reduced bone mass and impaired bone microarchitecture, thereby weakening bone strength and elevating fracture risk. Imbalanced bone remodeling is the major pathological mechanism of OP, in which osteoclast-mediated bone resorption exceeds osteoblast-mediated bone formation. Iron serves as a vital micronutrient for numerous biochemical activities and is essential for many cellular processes. Ferroptosis is an iron-dependent form of modulated cell death with unique traits, including disrupted iron balance, compromised antioxidant defenses, and aberrant lipid peroxidation. Ferroptosis participates in various physiological and pathological processes, and its role in bone-related diseases, particularly OP, is increasingly being explored. Hence, a systematic examination of the mechanisms modulating ferroptosis in OP is imperative to pinpoint potential therapeutic targets and innovate novel therapeutic and/or preventive strategies. The agents currently used to treat OP have numerous side effects, prompting increased research on natural compounds for OP treatment. This review systematically summarizes the key features and modulation mechanisms of ferroptosis based on the latest research advances, and explores its pathogenic implications and therapeutic opportunities in OP. Additionally, we also discussed investigations of natural products
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.